Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology

– Pure-Vu® System found to be simple, safe and effective in cleansing
inadequately prepared colons during a colonoscopy achieving a 98%
success rate in patients that had minimal bowel preparation –


– Data supports potential of Pure-Vu® System to improve clinical
outcomes while reducing costs and complications associated with
conventional purgative-based bowel preps in a market encompassing over
30 million annual procedures worldwide –

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus
GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a
medical technology company dedicated to improving clinical outcomes and
enhancing the cost-efficiency of colonoscopy, announced today that its
manuscript titled, “An
intra-procedural endoscopic cleansing device for achieving adequate
colon preparation in poorly prepped patients,” has been
published in the peer-reviewed Journal
of Clinical Gastroenterology.


The Company’s flagship product, the
Pure-Vu® System, is a U.S. FDA cleared medical device indicated to
help facilitate the cleaning of a poorly prepared colon during the
colonoscopy procedure. The device integrates with standard and slim
colonoscopes to enable safe and rapid cleansing during the procedure
while preserving established procedural workflow and techniques. The
Company is currently focused on post-approval clinical trials and market
development programs with leading U.S. hospitals that are utilizing the
Pure-Vu® System on a pilot basis in preparation for a full commercial
launch in the U.S. and select international markets in 2019.


Feasibility Study Data Highlights


The Pure-Vu® System significantly increased the number of subjects
with an adequate cleansing level (BBPS >= 2 for all 3 colon segments)
from 31% (15/49) at baseline to 98% (48/49) after use of Pure-Vu
(P